Epidemiological and clinical characteristics of inflammatory bowel diseases in Cairo, Egypt

Table 1 Demographic characteristics of ulcerative colitis patients in Cairo

	Ulcerative colitis patients
Mean age at presentation (yr)	27.3 (± 12)
Mean age at presentation (yr) (male:female)	29.2 (± 13.4):25.7 (± 10.6) P = 0.093
Mean age at presentation (yr) (urban:rural)	25.9 (± 9.7):27.9 (± 12.7) P = 0.394

Table 2 Sociodemographic and clinical data of ulcerative colitis patients

Total number	135
Gender (M/F)	63/72
Age at first presentation (mean ± SD)	27.3 ± 11.7
Resident of Cairo ( yes/no)	97/38
Smoking (yes/no)	14/121
Main presenting symptoms included: rectal bleeding, diarrhea, mucous, abdominal pain, loss of weight, fever	128/113/72/76/8/8
Follow up duration (mean ± SD)	6.2 ± 5.18
Severity of symptoms (true love classification) mild/moderate/severe	66/52/17
Anoperineal lesions (yes/no)	6/129
Hepatobiliary or pancreatic manifestations No/Fatty liver/sclerosing cholangitis	127/7/1
Other extra intestinal manifestations No/conjunctivitis/arthralgia/both	109/10/16/25
History of appendicectomy (yes/no)	18/117
Family history of UC (yes/no)	2/135
Extent of colitis Proctitis/left side colitis/pancolitis	25/88/22
Types of intestinal infections detected (total 31) Entameba histolytica/giardiasis/schistosomiasis	23/5/3

M: Male; F: Female; UC: Ulcerative colitis.

Table 3 Sociodemographic and clinical data of Crohn’s disease patient

Total number	22
Gender (M/F)	16/6
Age at first presentation (mean ± SD)	29.72 ± 12.13
Resident of cairo (yes/no)	21/1
Smoking (yes/no)	2/20
Main presenting symptoms included: diarrhea, colics, fever, WT loss, rectal bleeding, vomiting	22/18/9/10/6/4
Follow up duration (mean ± SD)	5.52 ± 2.83
Severity of symptoms (mild/moderate/severe)	9/11/2
Anoperineal lesions (yes/no)	8/14
Extra intestinal manifestations (yes/no) No/fatty liver/arthralgia/arthralgia and uveitis	8/1414/1/7/3
History of appendicectomy (yes/no)	3/19
Montreal classification:
A1/A2/A3	2/14/6
B1/B2/B3 /P>>	16/5/1/8
L1/L2/L3/L4>>	6/3/13/2
Endoscopic grading (mild/moderate/severe)	4/13/5
Follow up endoscopy (stationary/improved/ progressed/did not do)	2/15/2/3
Localization of sites of CD affection Ileal/ileocolonic/colonic/oesophageal	6/13/3/2
Types of intestinal infections detected (total 9) Entameba histolytica/schistosomiasis	7/2

M: Male; F: Female; CD: Crohn’s disease.

Table 4 Clinical scoring of the endoscopic findings of ulcerative colitis patients according to the Montreal classification

Number of patients/extent of colitis (endoscopic grading according to the Montreal classification)	E1 (Proctitis) (25 patient, 18.5%)	E2 Left side colitis (88 patient, 65.2%)	E3 Pancolitis (22 patient, 16.3%)
Number of patients/severity of colitis (endoscopic grading according to the Montreal classification)	Mild (25 patient, 18.5%)	Moderate (94 patient, 69.6%)	Severe (16 patient, 11.9%)
Follow up endoscopic grading
Stationary/improved/progressed/did not do			20/83/6/26

Table 5 Type of treatment, relapses, histopathological and laboratory findings of ulcerative colitis patients

Treatment used: (single drug or combinations) Oral 5-ASA ±, 5-ASAenemas or supp., prednisone, azathioprine, corticosteroids enemas. (Infliximab was used in 2 cases)
Surgical interference (yes/no)	4/131
Relapses (mean ± SD)	1.514 ± 1.575
Relapses (median/minimum/maximum)	1/0/10
Malignant transformation	1
Mean ESR 1st hour (mean ± SD)	36.37 ± 24.73
CRP (positive/negative/not done)	39/34/60
ANCA (positive/negative/not done)	12/28/95
ASCA (positive/negative/not done)	8/31/96
Pathological findings included: Vascular congestion, Crypt abscesses, Mucin depletion, Cellular infiltrate, Cryptitis, Crypt branching
Pathology (diagnostic/suggestive/non conclusive)	78/43/14
Mean Hemoglobin concentration, gm/dL (mean ± SD)	11.2 ± 2.8
Mean PLT count (mean ± SD)	335428.6 ± 140119.1
Mean TLC (mean ± SD)	8875 ± 4059.67

ASA: Aminosalicylic acid; CRP: C-reactive protein; ANCA: Anti-neutrophil cytoplasmic antibodies; ASCA: Anti-Saccharomyces cerevisiae antibodies.

Table 6 Type of treatment, relapses, histopathological and laboratory findings of Crohn's disease patients

CDAI (mean ± SD)	108.21 ± 53.84
CDAI (median/minimum/maximum)	103.33/38/259.5
Treatment used: (single drug or combinations) oral 5-ASA ± Metronidazole, ciprofloxacin, azathioprine, prednisone, infliximab,
surgical interference (yes/no)	7/15
Relapses (mean ± SD)	1.68 ± 2.21
Relapses (median/minimum/maximum)	1/0/8
Malignant transformation	None
Mean ESR 1st hour (mean ± SD)	49.52 ± 30.98
CRP (positive/negative)	17/5
ANCA (positive/negative/not done)	6/16
ASCA (positive/negative)	4/18
Pathological findings included: cellular infiltrate, focal inflammation, microfisttulization, non caseating granulomas, cobblestoning, lymphoid hyperplasia
Pathology (diagnostic/suggestive/non conclusive)	7/8/7
Mean hemoglobin concentration, gm/dL (mean ± SD)	11.95 ± 2.14
Mean PLT count (mean ± SD)	296272.72 ± 146308.60
Mean TLC (mean ± SD)	7868.57 ± 2708.17

CDAI: Crohn’s disease activity index; ASA: Aminosalicylic acid; CRP: C-reactive protein; ANCA: Anti-neutrophil cytoplasmic antibodies; ASCA: Anti-Saccharomyces cerevisiae antibodies.